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Collagens have previously been over-
looked for roles in the brain since fibril-
lar collagens, the best known and most 
widely studied example of collagens, 
are not present in the mature central 
nervous system. However, over the 
last decade it has become increasingly 
apparent that collagens are not merely 
structural proteins giving strength to 
tissue, but bio-active molecules with a 
dynamic role within the nervous sys-
tem. Collagen XVII particularly has 
been emerging as a putative antigen 
common to both dermatological and 
neurological disease. In this thesis 
these lines of thought found support as 
collagen XVII was found to be widely 
expressed in neurons of the human 
brain. Its exact function in the brain, 
however, remains unknown. 
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ABSTRACT 
Collagens have previously been overlooked for roles in the brain since fibrillar collagens, 
the best known and most widely studied example of collagens, are not present in the 
mature central nervous system (CNS). However, over the last decade it has become 
increasingly apparent that collagens are not merely structural proteins giving strength to 
tissue, but bio-active molecules with a dynamic role within the CNS. In fact, a role in the 
CNS, albeit often transient, has been identified for nearly every type of collagen during 
some phase of CNS development. Thus, collagens are now thought to have a decisive role 
in various aspects of neural maturation and are currently being studied in relation to 
various neurological disorders. 
Collagen XVII is one of the four non-fibril-forming transmembrane collagens, which 
function as both matrix proteins and cell-surface receptors. It is known to be a structural 
component of hemidesmosomes, which mediate adhesion of epidermal keratinocytes and 
certain other epithelial cells to the underlying basement membrane. Based on numerous 
case, animal and epidemiological studies, collagen XVII could be one of the most 
interesting putative antigens common to both dermatological and neurological disease.  
In this thesis, collagen XVII was studied in the mature human brain, using brain samples 
obtained at autopsy and an array of standard histological and molecular research methods. 
The aim was to establish whether collagen XVII is present in the human central nervous 
system and if so, to define the anatomical regions, cells and intracellular locations in which 
it is expressed. Also, possible changes in expression due to motor neuron disease-related 
neuropathology, as visualized with p62, were studied. 
This study found that collagen XVII is expressed in human CNS neurons and that it is 
widely distributed in different anatomical regions of the human brain. Intraneuronally, the 
immunoreactivity is localised to lipofuscin granules. The study also established that the 
expression of collagen XVII is not altered in motor neuron disease and that the presence of 
p62- positive inclusions outside the motor system in motor neuron disease could be a 
marker for psychiatric morbidity.  
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TIIVISTELMÄ 
 
Kollageenit ovat aiemmin jääneet huomiotta aivotutkimuksen saralla, sillä 
kollageenisäikeitä, kollageenien tunnetuinta esiintymismuotoa, ei kypsässä 
keskushermostossa esiinny. Viime vuosikymmenen aikana on kuitenkin käynyt ilmeiseksi, 
että kollageenit eivät ainoastaan strukturoi ja vahvista kudoksia, vaan ovat bioaktiivisia 
molekyylejä joilla on dynaaminen rooli keskushermossa. Itse asiassa, lähes jokaisella 
kollageenityypillä on jonkinlainen rooli keskushermoston kehityksessä, joskin useimmiten 
vain väliaikaisesti ja vain tietyssä kehitysvaiheessa.  Näin ollen nykyisin kollageeneilla 
ajatellaan olevan merkittäviä tehtäviä hermoston kypsymisessä ja kollageeneja on alettu 
tutkia erilaisten hermostollisten sairauksien yhteydessä. 
Kollageeni XVII on yksi neljästä transmembraani kollageenista. Nämä kollageenit eivät 
muodosta säikeitä ja toimivat sekä soluvälitilaproteiineina, että solukalvoreseptoreina. 
Kollageeni XVII:n tiedetään olevan osa hemidesmosomia, joka toimii sitomalla 
keratinosyyttejä ja tiettyjä muita epiteelisoluja niiden alaiseen tyvikalvoon. Useat 
epidemiologiset tutkimukset, tapausselostukset ja eläinkokeet viittaavat siihen, että 
kollageeni XVII voisi toimia antigeeninä sekä hermostollisissa sairauksissa, että 
ihotaudeissa.  
Tässä väitöskirjassa tyypin XVII kollageenia tutkittiin kypsissä ihmisen aivoissa, 
käyttäen ruumiinavauksissa otettuja aivonäytteitä sekä valikoimaa vakiintuneita 
histologisia ja molekylaarisia tutkimusmenetelmiä. Tarkoituksena oli tutkia esiintyykö 
kollageeni XVII ihmisen keskushermostossa ja jos esiintyy, niin millä anatomisilla alueilla, 
missä soluissa ja missä solunosassa. Myös mahdollisia muutoksia kollageeni XVII:n 
ekspressiotasossa suhteessa p62-visualisoituihin motoneuronitautimuutoksiin tutkittiin. 
Tutkimus toi esiin, että kollageeni XVII esiintyy ihmisen aivojen neuroneissa useilla eri 
aivoalueilla. Solunsisäisesti kollageeni XVII sijaitsee lipofuskiinirakkuloissa. Tutkimus 
osoitti myös, ettei kollageeni XVII:n ekspressiotaso muutu motoneuronitaudissa ja että p62-
positiivisten inkluusioiden läsnäolo motoristen aivoalueiden ulkopuolella 
motoneuronitaudissa voi liittyä psykiatriseen oireiluun.  
 
 
Luokitus: QW 504.5, QZ 35, WE 550, WL 300 
Yleinen Suomalainen asiasanasto: amyotrofinen lateraaliskleroosi; aivot; ihminen; kollageenit; ruumiinavaus; 
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1 Introduction 
Collagens have generally been overlooked for roles in the brain since fibrillar collagens, the 
best known and most widely studied example of collagens, are not present in the mature 
central nervous system (CNS). However, over the last decade it has become increasingly 
apparent that collagens are not merely structural proteins giving strength to tissue but bio-
active molecules with a dynamic role within the CNS (Fox 2008, Hubert et al. 2009).  
Previously, collagen XVII has primarily been studied in relation to blistering skin 
diseases. It is abundantly expressed in the skin, which is ectodermal in origin, as is the 
nervous system. This common ontogenetic background could be one of the reasons behind 
the often noted connection between psychiatric and dermatological symptomology (Locala 
2009) and explain neuro-dermatological disease associations via immunological pathways 
to common antigens (Sperner-Unterweger 2005). Based on numerous case-, animal and 
epidemiological studies, collagen XVII could be one of the most interesting putative 
antigens common to both dermatological and neurological disease (see for example 
Claudepierre et al. 2005, Langan et al. 2011, Li et al. 2009, Stinco et al. 2005).  
In this thesis, collagen XVII was studied in the mature human brain, using brain tissue 
samples obtained at autopsy and an array of standard molecular and histological research 
methods, such as RT-PCR, immunohistochemistry and electron microscopy. The associated 
literature review provides an overview of the current evidence pointing toward 
immunologically mediated neuro-dermatological interactions in various pathological 
states.
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2 Review of the literature 
2.1 COLLAGENS 
Collagens, the most abundant protein in the human body (Myllyharju and Kivirikko 2004), 
and, in fact, on earth (Buehler 2006), are a family of extracellular or transmembrane proteins 
made up of three polypeptide strands called α-chains. These three chains, which in most 
collagen types are identical (Kadler et al. 2007), twist together with the aid of hydrogen 
bonds in order to create a triple helix. The final superstructural folding of the triple helix in 
each type of collagen is determined by the α-chains’ distinguishing type of Gly-X-Y 
repetition, where X and Y can represent any amino acid but Y is often proline or 4-
hydroxyproline. Some collagens have an uninterrupted stretch of Gly-X-Y triplets whereas 
some, such as collagen XVII, present with several stretches, interrupted by non-
collageneous sequences (Hubert et al. 2009). All collagens have non-collagenous domains at 
their N- and C-termini (Kadler et al. 2007).  
That having been said, there is no universally accepted definition for a collagen. The 
distinction between proteins accepted into the collagen family and other proteins with 
collagenous, triple-helical domains is blurred (Kadler et al. 2007). The current literature 
accepts that there are 29 collagen types,  although it has been argued that type XXIX is not, 
in fact, a distinct collagen subtype but a variant of collagen VI (Fitzgerald et al. 2008). In any 
case, the collagens differ from each other significantly in size, structure and function 
(Hubert et al. 2009). Because of their ability to form superstructures, the collagens can be 
further divided into seven subfamilies, based on their varying functional roles (Table 1). 
The role collagens are best known for is forming fibrils and assembling into elongated 
fibres in the extracellular matrix in order to add structural strength to connective tissues 
(Fox 2008).  
2.2 COLLAGENS IN THE NERVOUS SYSTEM 
In the nervous system, collagens have traditionally been thought to occupy a marginal 
position, such as the basement membrane in the blood-brain barrier between vascular and 
neural tissues (Cardoso et al. 2010), the meninges (Sajanti et al. 1999) and around sensory 
end organs such as inner ear hair cells, skin receptors and muscle spindles (Cueva et al. 
2007, Russell et al. 2007). In mature brain tissue itself, fibrillar collagen is absent (Hubert et 
al. 2009).  
However, collagens are not merely structural molecules, but bio-active adhesion 
molecules. Indeed, the non-structural activities of collagens within the nervous system have 
become more of a focus of interest in the last decade, as many recently discovered collagens 
are not assembled into fibers (Kadler et al. 2007, Myllyharju and Kivirikko 2004) and some 
of them are expressed by neurons themselves (Claudepierre et al. 2005, Hashimoto et al. 
2002, Sund et al. 2001). Functions such as establishment of brain architecture (Sertie et al. 
2000), neuronal differentiation (Ali et al. 1998), regulation of axonal outgrowth (Schneider 
and Granato 2006) and targeting (Xiao and Baier 2007) and synaptic differentiation (Fox et 
al. 2007) have been attributed to various types of collagen. In fact, a role in the CNS, albeit 
often transient, has been identified for nearly every type of collagen during some phase of 
CNS development (Table 1). Thus, collagens are now thought to have a decisive role in 
various aspects of neural maturation (Fox 2008, Heffron et al. 2009).   
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Table 1. The 29 collagen types and their division into seven subfamilies. Adapted from the 
following reviews: Hubert et al. (2009), Fox (2008) and Kadler (2007). 
 
Type 
Major 
expression 
site(s) 
Expression and/or 
role in the nervous 
system 
References  
 
1. Fibril-forming collagens 
 
Collagen I Bone, skin, 
tendon, arteries, 
intestine, 
tendon, ligament 
Expressed in the 
meninges. Neurologic 
defects in osteogenesis 
imperfecta. Intracranial 
aneurysms associated 
with certain COL1A2 
polymorphisms.  
(Charnas and Marini 
1995, Ruigrok and 
Rinkel 2008, Sajanti 
et al. 1999) 
Collagen II Cartilage Expressed in the brain 
during embryogenesis. 
(Leung et al. 1998) 
Collagen III Co-distributes 
with type I 
except absent in 
bone and tendon 
Expressed in the 
meninges. 
(Myllyharju and 
Kivirikko 2001, 
Sajanti et al. 1999) 
Collagen V Cornea, co-
distributes with 
type I 
Expressed in Schwann 
cells, regulates axonal 
outgrowth and 
Schwann cell 
migration. 
(Chernousov et al. 
2001) 
Collagen XI Co-distributes 
with type II  
Expressed in the brain 
during embryogenesis. 
(Lui et al. 1995) 
Collagen XXIV Bone, cornea None known. (Matsuo et al. 2008) 
Collagen XXVII Cartilage in 
adult, varying 
tissues during 
embryogenesis 
mRNA expressed in 
brain during 
embryogenesis. 
(Boot-Handford et 
al. 2003, Plumb et 
al. 2007) 
 
2. Beaded-filament forming collagens 
 
Collagen VI Most connective 
tissues and 
muscle 
Regulates Schwann cell 
differentiation. 
(Vitale et al. 2001) 
Collagen XXVI Testis, ovaries None known. (Sato et al. 2002) 
Collagen XXVIII Peripheral 
nervous system 
Basement membrane 
around Schwann cells. 
(Veit et al. 2006) 
Collagen XXIX Skin, lung, the 
gastrointestinal 
tract 
None known. (Soderhall et al. 
2007) 
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3. Network-forming collagens 
 
Collagen IV Ubiquitous tissue 
distribution in 
basement 
membranes 
Col4a1 mutations 
cause porencephaly 
and cerebral 
vasculopathy. Present 
in pia mater and 
subependymal 
basement membrane. 
Role in neuronal 
differentiation. 
(Ali et al. 1998, 
Gordon and Hahn 
2010, Gould et al. 
2005, Lanfranconi 
and Markus 2010, 
Urabe et al. 2002) 
Collagen VIII Eye, skin , 
glomeruli 
Expressed in 
meninges and spinal 
cord. Expressed in 
blood vessels of 
various kinds of brain 
tumors. 
(Gordon and Hahn 
2010, Kapoor et al. 
1988, Paulus et al. 
1991) 
Collagen X Hypertrophic 
cartilage 
None known. (Gordon and Hahn 
2010) 
 
4. Fibril-associated collagen with interrupted triple helices and related 
collagens 
 
Collagen IX Co-distributes with 
type II 
Possibly contributes to 
segmentation of 
peripheral nervous 
system, expressed by 
meninges. 
(Ring et al. 1996, 
Ring et al. 1995) 
Collagen XII Co-distributes with 
type I 
Present in meninges 
during development. 
(Berthod et al. 1997, 
Oh et al. 1993, 
Walchli et al. 1994) 
Collagen XIV Co-distributes with 
type I 
Present in nervous 
tissue during 
development. 
(Berthod et al. 1997, 
Walchli et al. 1994) 
Collagen XVI Skin, heart, 
kidney, intestine, 
ovary, testis, eye, 
arterial walls and 
smooth muscles 
Low expression in 
normal brain, strongly 
upregulated in 
gliomas. 
(Bauer et al. 2011, 
Grassel et al. 1999, 
Lai and Chu 1996) 
Collagen XIX Muscle, basement 
membrane zone 
Expressed by 
interneurons and 
contributes to 
formation of 
hippocampal 
synapses. 
(Su et al. 2010) 
Collagen XX Widespread, 
especially corneal  
epithelium 
None known. (Koch et al. 2001) 
Collagen XXI Widespread Low expression in 
brain. 
(Fitzgerald and 
Bateman 2001) 
Collagen XXII Tissue junctions None known. (Koch et al. 2004) 
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The human genes coding for the ca. 40 distinct α-chains appearing in the different collagens are 
expressed as, for example, COL1A2, where the first arabic numeral stands for the collagen type 
and the second for the number of the α-chain (Myllyharju and Kivirikko 2004).  
 
5. Transmembrane collagens 
 
Collagen XIII Neuromuscular 
junctions, skin 
Expressed in nervous 
system. 
(Sund et al. 2001) 
Collagen XVII Epithelium, see 
text 
Expressed in brain 
and retina, see text. 
(Claudepierre et al. 
2005) 
Collagen XXIII Lung, cornea, 
brain, skin, 
tendon, kidney 
Expressed in brain. (Koch et al. 2006) 
Collagen XXV Amyloid plaques in 
brain 
Associated with 
Alzheimer’s disease 
pathology. 
(Forsell et al. 2010, 
Hashimoto et al. 
2002, Tong et al. 
2010) 
 
6. Multiplexin collagens 
 
Collagen XV Eye, heart, skeletal 
muscle, 
microvessels 
Expressed in brain 
vasculature. 
(Muona et al. 2002, 
T. Sasaki et al. 
2000) 
Collagen XVIII Ubiquitous tissue 
distribution in 
basement 
membranes 
Mutations responsible 
for neural tube 
defects (Knobloch 
syndrome). Present in 
amyloid plaques in 
Alzheimer’s disease 
and brains affected 
with cerebral malaria 
and traumatic injury.  
(T. Sasaki et al. 
2000, Seppinen and 
Pihlajaniemi 2011, 
Sertie et al. 2000, 
van Horssen et al. 
2002) 
 
7. Anchoring fibril-forming collagen 
 
Collagen VII Skin, cornea and 
several other 
epithelial tissues 
Expressed in choroid 
plexus epithelial cells, 
around the pineal 
gland and pituitary 
gland cell nests.  
(Paulus et al. 1995, 
Uitto and Pulkkinen 
1996) 
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2.3 COLLAGEN INVOLVEMENT IN NEUROLOGICAL DISORDERS 
To date, most CNS pathology associated with collagens is developmental in origin, in line 
with the role that collagens have in neurodevelopment (Table 1, collagens I, IV and XVIII). 
A notable exception is Alzheimer’s disease. In the extracellular plaques present in brains 
with Alzheimer’s disease, a collagenous component called CLAC (collagenous Alzheimer 
amyloid plaque component) is present (Hashimoto et al. 2002). CLAC is the furin-cleaved 
extracellular part of the transmembrane collagen XXV, which is expressed by neurons. 
Interestingly, COL25A1 alleles have been associated with increased risk for Alzheimer’s 
disease (Forsell et al. 2010) and over-expression of the Col25a1- gene in mice leads to 
Alzheimer’s disease-like brain pathology (Tong et al. 2010). 
 Although these non-structural functions of collagens in the CNS have gained attention 
recently, fibrillar collagens have also been studied in relation to neurological disease. In 
fact, cutaneous involvement in the motor neuron disease (MND) amyotrophic lateral 
sclerosis (ALS) was first suggested as early as 1880, prompted by the lack of bedsores in 
ALS patients (Charcot 1880). Contemporary clinicians have also noted that the skin of ALS 
patients feels supple and loses elasticity. When the skin is stretched, it returns only 
sluggishly to its original position (Ono 2007). Accordingly, several studies have pointed 
towards cutaneous and collagen involvement in MND. Using light and electron microscopy 
Ono and colleagues (1998, 1990, 1986) found abnormalities in the amount and diameter of 
fibril-forming collagens in both the skin and perivascular spaces of the spinal cord in ALS 
patients, whereas Ono and Yamauchi (1992) showed that there was an increased amount of 
immature soluble collagen in relation to the duration of illness in the skin of ALS patients. 
Also, irregularity in dermal collagen fibrils has been reported (Kolde et al. 1996, Provinciali 
et al. 1994, Watanabe et al. 1987). Furthermore, the amount of collagen-associated amino 
acids is markedly decreased in the lateral corticospinal tract and the anterior horn of ALS 
patients (Ono et al. 1999) and the amount of glucosylgalactosyl hydroxylysine, a collagen 
metabolite, is decreased in the urine of ALS patients (Ono et al. 2001). These findings have 
suggested that an alteration of collagen metabolism takes place in ALS.  
Subarachnoid haemorrhage is followed by a transient increase in the rate of fibrillar 
collagen synthesis in both the arachnoid and the dura (Sajanti et al. 1999, Sajanti et al. 2000). 
The leptomeningeal cells and dural fibroblasts have thus a considerable potential for 
collagen synthesis and can function similarly to fibroblasts in other tissues during wound 
healing. Highly elevated levels of propeptides of procollagens have also been measured in 
chronic subdural haematoma (Sajanti and Majamaa 2003).  
Collagen aberrations have also been widely studied in relation to intracranial aneurysms 
and indeed intracranial aneurysms are a typical feature of the heritable connective tissue 
disorder Ehlers-Danlos syndrome type IV, which involves collagen mutations (Borck et al. 
2010). However, although connective tissue alterations have been found in skin biopsies 
from a minority of patients with intracranial aneurysms without Ehlers-Danlos syndrome 
(Grond-Ginsbach et al. 2002), no definite linkage between collagen- gene mutations and 
intracranial aneurysms has been established in the general population (Kuivaniemi et al. 
1993, Ruigrok and Rinkel 2008).  
2.4 COLLAGEN XVII 
Collagen XVII, also known as bullous pemphigoid antigen 2 (BPAG2) or BP180, is one of 
the four non-fibril-forming transmembrane collagens (Table 1), which function as both 
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matrix proteins and cell-surface receptors. In addition, there are also other transmembrane 
proteins, such as ectodysplasin-A and gliomedin that have not been accepted into the 
family of collagens, despite harbouring collageneous domains. All of these proteins exist in 
two different forms, one being a type II- oriented transmembrane protein and the other 
being a shorter soluble molecule derived by post-translational proteolysis (Franzke et al. 
2003, Hooper et al. 1997). Interestingly, all the transmembrane collagens have been shown 
to be present in the nervous system and gliomedin has been implicated in the genesis of the 
nodes of Ranvier (Maertens et al. 2007). 
The structure of collagen XVII, its binding ligands and pathological alterations in various 
genetic and acquired skin disorders have been described in detail (Franzke et al. 2005, 
Franzke et al. 2003). It is a homotrimer of three 180 kDa α1(XVII) chains, each with a long 
intracellular N-terminal domain of 466 amino acids, a short transmembrane stretch of 23 
amino acids and an extracellular C-terminus of 1008 amino acids (Giudice et al. 1992). 
Collagen XVII is known to be a structural component of hemidesmosomes, which mediate 
adhesion of epidermal keratinocytes and certain other epithelial cells to the underlying 
basement membrane.  
The intracellular component of collagen XVII interacts with the 4-integrin subunit, 
plectin, and BP230 (Hopkinson et al. 1998, Hopkinson and Jones 2000) to form a stable 
attachment of hemidesmosomes to keratin intermediate filaments within the cell (Figure 1). 
The 120-kDa ectodomain of collagen XVII binds to both the α6 integrin subunit (Hopkinson 
et al. 1995) and laminin 332, previously known as laminin 5 (Marinkovich 2007, Tasanen et 
al. 2004), and is constitutively shed from the cell surface by the metalloproteases ADAM 9 
and ADAM 10 (Franzke et al. 2009), yielding a soluble form of the molecule into the 
extracellular matrix (Franzke et al. 2002, Schacke et al. 1998). Although the physiological 
implications of the shedding are not certain, it has been proposed that this allows the 
anchored cell to detach, migrate and differentiate during morphogenesis and during 
regeneration in wound healing (Franzke et al. 2005, Tasanen et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of collagen XVII and its main ligands attaching intracellular 
intermediate filaments via hemidesmosomes to the basement membrane. 
Nc16a 
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Interestingly, ADAM 10 is expressed by both oligodendrocytes and developing neurons 
(Lin et al. 2008), and has several important functional roles in the CNS. These include 
processing of amyloid precursor protein (Marcello et al. 2007, Rosenberg 2009), 
involvement in neurogenesis and axon extension (Y. Y. Chen et al. 2007), the establishment 
of the brain cortex (Jorissen et al. 2010), spine maturation and control of the structure and 
function of glutamatergic synapses (Malinverno et al. 2010). 
Collagen XVII is abundantly expressed in the cell membranes of epithelia. It is 
particularly copious in the skin  (Nishizawa et al. 1993), but is also present in the human 
ocular cornea and conjunctiva, buccal mucosa, upper oesophagus, placenta, umbilical cord, 
urine bladder, (Fairley et al. 1995), bronchial epithelia (Michelson et al. 2000), amniotic fluid 
and fetal membranes (Huilaja et al. 2008) and the ring fibers of the spleen (Määttä et al. 
2004).  
In the nervous system, collagen XVII has been previously studied using bovine and rat 
tissue (Claudepierre et al. 2005). Collagen XVII was detected, often co-localizing with its 
epithelilal ligand BPAG1 and complexing with various laminins, in Muller glial cells, 
photoreceptors and synaptic regions of the retina, and the cerebellum.  
2.4.1 Collagen XVII in skin disease 
Lack of collagen XVII or the loss of its function results in diminished epidermal adhesion 
and skin blistering in response to minimal shearing forces. In non-Herlitz-type junctional 
epidermolysis bullosa this can be caused by mutations in the collagen XVII gene, COL17A1, 
leading to rudimentary hemidesmosomes and separation of the basal keratinocytes from 
the underlying basement membrane (Powell et al. 2005). In the pemphigoids, i.e. bullous 
pemphigoid, pemphigoid gestationis, linear IgA disease and mucous membrane 
pemphigoid, the cause can be autoimmunity against collagen XVII. The autoantibodies are 
primarily directed against two antigenic extracellular regions, namely the NC16a domain 
(Nishie et al. 2010) and the carboxyterminal domain (Figure 1), although reactivity to other 
parts has been reported (Patricio et al. 2009, Powell et al. 2005).  
Among pemphigoids, bullous pemphigoid is the most frequent, with a reported annual 
incidence of 43 per million population in the UK (Taghipour et al. 2010) and six to seven 
cases per million population in France and Germany. It usually affects the elderly, and both 
sexes are similarly affected. Clinically, BP is characterized by tense blisters, variably 
associated with severe itching. In most BP- cases serological diagnostics reveal circulating 
autoantibodies (Leuci et al. 2010), and the examination of the skin by direct 
immunofluorescence shows linear complement C3 deposition along the basement 
membrane and in most cases IgG as well (Kirtschig et al. 2010).  
In addition to collagen XVII, autoantibodies in bullous pemphigoid can be directed 
against BP230, also called BPAG1 or dystonin. Interestingly, BP230 has an isoform 
expressed by neurons and is implicated in dystonia musculorum in mice (Brown et al. 
1995). BP230 belongs to the plakin family of cytolinkers and interacts with collagen XVII in 
hemidesmosomes (Figure 1.), functioning as a cytoskeletal organizer (Brown et al. 1995, 
Thoma-Uszynski et al. 2004). It is noteworthy that there is no significant nucleotide or 
amino acid sequence homology between collagen XVII and BP230 (Yamada et al. 1996). 
2.4.2 Bullous pemphigoid and neurological disorders 
In line with the findings associating ALS and collagen abnormalities, Chosidow at al. (2000) 
suggested an association between pemphigoid and ALS by reporting 3 cases of BP and 2 
cases of dyshidrosiform pemphigoid, an unusual localised variant of BP, in a population of 
168 French ALS patients.  
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More robust statistical associations between BP and other neurological disorders have 
also been repeatedly implied (Table 2). Foureur et al. (2001) found neurological disorders in 
30 out of 46 consecutive day-unit patients with BP, chief amongst which were senile 
dementia (17/46) and cerebral stroke (6/46). Likewise, Cordel (2007) found that that 123 
(36%) of 341 BP patients from French dermatology departments  had a neurological 
disorder: 68 (55%) of these were dementia, primarily Alzheimer’s disease followed by 
vascular dementia, and (52) 42% were cerebral stroke. These findings were repeated by 
Jedlickova et al. (2010). Their analysis showed that psycho-neurological disease, again 
primarily cerebral stroke and dementia, was found in 42.7% of 89 BP patients and in 19.1% 
of controls. Similar figures were reported by Taghipour et al (2010): at least one 
neurological disease was present in 46% of 90 consecutive BP patients from an 
immunobullous referral centre, as compared to 11% in controls. Identically, a statistically 
significant association with BP was found for cerebrovascular disease and dementia.  
Dementia, or severe cognitive impairment, has since been consistently reported in 
association with BP in three more studies (Bastuji-Garin et al. 2011, Y. J. Chen, Wu et al. 
2011, Langan et al. 2011) and a case-report (Kanda et al. 2010). What is more, a study of 138 
elderly subjects with no dermatological symptoms discovered that the presence of anti-
collagen XVII antibodies in the serum was significantly correlated with a mini-mental test 
score of under 24/30, i.e. the cut-off score for dementia (Foureur et al. 2006).  
 
 
Table 2. Epidemiological studies linking bullous pemphigoid and neurological morbidity. 
 
 
Reference Country 
of study 
Type of study Number of BP 
cases in study 
Neurological disorders 
associated to BP  
Foureur et al., 
2001 
France Retrospective 
case-control 
46 Senile dementia/Alzheimer 
Cerebral stroke 
Stinco et al., 
2005 
Italy Retrospective 238 Multiple sclerosis 
Parkinson’s disease 
Cordel et al., 
2007 
France Retrospective 341 Dementia  
Cerebral stroke 
Parkinson’s disease or parkinsonism 
Jedlickova et 
al., 2010 
Czech 
Republic 
Retrospective 
case-control 
89 Dementia 
Cerebral stroke 
Taghipour et 
al., 2010 
UK Retrospective 
case-control 
90 Cerebrovascular disease 
Dementia 
Langan et al.,  
2011 
UK Retrospective 
population 
based  
case-control 
868 Dementia 
Parkinson’s disease 
Stroke  
Epilepsy 
Bastuji-Garin  
et al., 2011 
France Prospective 
case-control 
201 Severe cognitive impairment (MMSE  
<17) 
Parkinsons’ disease 
Uni- or bipolar disorder 
Chronic neuroleptic drug use 
Chen Y.J. et al., 
2011 
Taiwan Retrospective 
population 
based 
case-control 
3485 Dementia 
Stroke 
Schizophrenia 
Epilepsy 
Parkinson’s disease 
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A retrospective study on the discharge records of all hospitalised patients in a region in 
northern Italy of ca. 1 200 000 inhabitants during a 5-year period supported an association 
between bullous pemphigoid, multiple sclerosis and Parkinson’s disease (Stinco et al. 2005). 
In line with these findings, the literature reports several cases of bullous pemphigoid 
developing in patients with multiple sclerosis (Kirtschig et al. 1995, Simjee et al. 1985, Stinco 
et al. 2002) and at least one in a patient with Parkinson’s disease (Forschner et al. 2002). The 
association of Parkinson’s disease with bullous pemphigoid has been subsequently 
reported in epidemiological studies by others as well (Bastuji-Garin et al. 2011, Y. J. Chen, 
Wu et al. 2011, Cordel et al. 2007, Langan et al. 2011). There are also case reports of 
unilateral BP on the paralysed side of hemiplegic patients (Bunker and Brown 1993, 
Foureur et al. 2001, Long et al. 1992).  
Psychiatric morbidity may also be associated with BP (Wijeratne and Webster 1996). 
Bastuji-Garin found that unipolar or bipolar mood disorders and the use of psycholeptics, 
particularly neuroleptics, were a risk factor for BP in the elderly (2011, 1996). One large 
study has also associated schizophrenia with BP in females (Y. J. Chen, Wu et al. 2011). 
Although BP usually affects people over 65 years of age, cases among younger people 
are not unheard of. Interestingly, a retrospective study of 74 patients with BP before 60 
years of age found neurological disorders in 12 and use of psychiatric drugs in 33 cases 
(Bourdon-Lanoy et al. 2005) (not included in Table 2 due to age-difference of cases as 
compared to the other studies). 
2.5 VISUALIZATION OF NEURONAL LESIONS IN NEURODEGENERATIVE 
DISEASES 
Neurodegenerative disorders, clinically characterized by dementia and/or motor 
syndromes, each present with characteristic gross and microscopic lesions in distinct cell 
populations and anatomical regions of the brain. This enables diagnostic distinction 
between various diseases and what can be considered as normal variability and changes 
due to aging (Fjell and Walhovd 2010). For instance, in Alzheimer’s disease cortical atrophy 
is most  pronounced in the frontal, parietal and temporal lobes, whereas in corticobasal 
degeneration depigmentation of the substantia nigra and asymmetric frontoparietal 
atrophy is typically seen (Tolnay and Probst 2003).  In addition to neurodegeneration and 
resulting gross atrophy, neurodegenerative diseases are characterized by various types of 
cytoplasmic or intranuclear inclusions. Inclusions are abnormal accumulations of 
intracellular constituents, primarily ubiquitinated proteins, appearing as discrete bodies 
within the neuron when visualized in tissue sections using IHC (Alves-Rodrigues et al. 
1998, Lowe 1998).  
Ubiquitin is a small protein with which other proteins are marked for degradation in the 
ubiquitin-proteasome degradation pathway, which is one of the two main pathways of 
degradation of intracellular components. This pathway plays a crucial role in the selective 
degradation of short-lived regulatory proteins and abnormal proteins that need to be 
eliminated from the cells (S. Sasaki 2011). The ubiquitinated protein accumulations 
mentioned above are thought to result from dysfunction of the ubiquitin-proteasome 
degradation pathway or from structural changes in the protein substrates that prevent their 
degradation. Impairment in autophagy, the other main degradation pathway, has also been 
implicated in the formation of the ubiquitinated protein aggregates (Myeku and 
Figueiredo-Pereira 2011). In contrast to the ubiquitin-proteasome system, autophagy is 
generally thought to be a less selective degradation system, as it can deal with entire 
portions of cytoplasmic organelles (S. Sasaki 2011). 
In MND, by definition, upper or lower motor neuron lesions with corticospinal tract 
degeneration are seen. In addition, distinctive neuronal cytoplasmic inclusions (NCI) are 
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visualized in both sporadic and familial cases of MND by applying ubiquitin or TAR DNA-
binding protein 43 (TDP-43) IHC. TDP-43 is a nuclear factor that functions in regulating 
transcription and alternative splicing, but in sites affected by MND it is mislocalized to the 
cytoplasm where it aggregates into inclusions (Ito and Suzuki 2011). However, it has 
become evident that TDP-43-positive inclusions are not present only in MND but also in a 
high proportion of cases with frontotemporal lobar degeneration with ubiquitinated, tau-
negative inclusions (FTLD-U) (Arai et al. 2006). Based on these findings, an appreciation of 
a common neuropathological spectrum encompassing FTLD-U, FTLD-MND/ALS and 
MND (King et al. 2010) has developed, dubbed TDP-43 proteinopathies (Arai et al. 2006), 
which not only affect the motor system, but rather are multisystem proteinopathies (Geser 
et al. 2008). The common core of the neurodegenerative cascade associated with this 
disease-entity is thought to be an impairment of the RNA quality control system (Ito and 
Suzuki 2011).  
2.5.1 p62 
Likewise, the ubiquitin binding protein p62/sequestosome 1 (p62) has been shown to be a 
component of NCIs in neurodegenerative disorders, including MND (Arai et al. 2003, 
Furukawa et al. 2004, Mizuno et al. 2006, Parkinson et al. 2006, Seelaar et al. 2007). In fact, 
there are reports that p62-IHC can visualize TDP-43-negative inclusions within the 
cerebellum in a proportion of cases across the range of the TDP-43 proteinopathy spectrum 
(King et al. 2010, Pikkarainen, Hartikainen et al. 2010). In addition, it has been reported that 
p62-immunoreactive (IR) pathology is seen in MND not only in the pyramidal motor 
system but more widely in the CNS (Hiji et al. 2008). Because of its wide ability to readily 
visualize neuropathological inclusions, p62 has been promoted as a “general inclusion 
stain” (Kuusisto et al. 2008). 
Physiologically, p62 is a multidomain signaling adaptor that functions as an organizer of 
receptor-mediated signalling in cells (Kuusisto et al. 2008). It is best-known for its function 
in the regulation of atypical protein kinase C in response to cell-surface receptor 
stimulation. By thus interacting and mediating in many different cellular pathaways, such 
as autophagy and the ubiquitin-proteasome pathway, it has a critical role in the control of 
cell survival and death (Moscat and Diaz-Meco 2009). p62 mRNA is ubiquitously expressed 
in human tissues (Joung et al. 1996).  
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3 Aims of the study 
The molecular features and ligands of collagen XVII are well characterized, as is its 
necessity for epidermal stability. Previous studies have indeed mainly focused on epithelia, 
while very little is known about collagen XVII in neural tissue. However, earlier studies 
have implied that collagen XVII could have a functional and neuropathological role in the 
human central nervous system. 
 
The aims of the study were: 
 
1. To study whether or not collagen XVII is expressed in the human central nervous  
system (study I).  
 
2. To define in which cells and anatomical regions in the human brain collagen XVII  
is expressed (study II). 
 
3. To define the intraneuronal location of collagen XVII (study III). 
 
4. To detect any change in neuronal collagen XVII- expression in motor neuron  
disease (study IV). 
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4 Materials and methods 
4.1 SUMMARY 
A summary of the main materials, methods and purpose of each step in this study is given 
in Table 3, and the details are described in the following chapters. In short, the materials in 
this study consisted of both pathological and neuropathologically unimpaired human brain 
samples, in which the presence of collagen XVII and its RNA were detected with several 
methods.   
4.2 HUMAN BRAIN SAMPLES 
4.2.1 Samples of normal brain obtained at forensic autopsy (I) 
As the first step in the study, ten human brain samples were obtained at autopsy in the 
Department of Forensic Medicine, University of Oulu. The autopsies were performed as 
part of the Finnish death investigation procedure and as such the cases represented a wide 
age group (21-75 years at death) of neuropathologically healthy individuals with a very 
short agonal period and a low probability of suffering from diseases that could compromise 
tissue quality.  
The brain samples were dissected by a forensic pathologist and obtained within 6-51 
hours (median 29h) post-mortem. Deceased that posed a risk of infection or had any 
neurological diagnoses indicating pre-mortem brain pathology were excluded from the 
study.  Demographics of each subject including gender, age at death, cause of death, mode 
and rapidity of death and post-mortem delay are given in the original publication (I). IHC 
detecting astrocytes and microglia detected a small infarct in one case, but all samples 
fulfilled the quality requirements for molecular and histological studies (Hynd et al. 2003). 
At this point of the study the focus was simply whether or not collagen XVII could be 
detected in the human brain. Therefore two anatomical regions sufficed: the cortex and the 
basal forebrain. In each case cortical brain samples were taken from both the frontal and 
temporal lobe. Samples from the amygdaloid complex were obtained in three random 
cases. The samples were fixed in formalin and embedded in paraffin and consecutive 
sections of 3-4 m thickness were cut to be used for routine histochemical stainings, in situ 
hybridisation and immunohistochemistry (IHC). Furthermore, two additional hippocampal 
and amygdaloid samples were snap frozen to be used for reverse transcriptase-polymerase 
chain reaction (RT-PCR). Hematoxylin-eosin (HE) and cresyl fast violet stains were used to 
evaluate the basic histology of the paraffin embedded samples and to identify the 
neuroanatomical structures.  
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4.2.2 Samples of normal brain obtained at clinical autopsy (II, III)
In order to study the distribution of collagen XVII more widely in the human brain, 12 cases 
were chosen from the Kuopio Brain Bank. All subjects, aged from 17 to 78 years at death 
from cardiovascular causes, lacked any signs of neurological dysfunction. Routine gross- 
and microscopic neuropathological assessment, using β-amyloid, α-synuclein and 
hyperphosphorylated tau- IHC, did not reveal any disease- or age-related 
neuropathological changes. The deaths had been virtually instantaneous in seven subjects; 
three subjects had died within 24 h with no evidence of cerebral hypoxia and one subject 
displayed evidence of final cerebral hypoxia. The mode of death was categorized as 
previously described (Hynd et al. 2003).
The brains (n=11) were fixed at autopsy with 10% buffered formalin by in situ perfusion 
via the carotid artery for 1 h in order to achieve consistent fixation throughout the entire 
brain. The brains were then removed, weighed and fixed in 10% buffered formalin for 23 to 
65 days. After fixation, the brains were grossly evaluated, cut into coronal slices and 
examined for macroscopically detectable lesions. The same neuropathologist dissected all 
the brains, using a standardized sampling protocol. Brain specimens were taken from 
cortical, subcortical and subtentorial gray matter structures as follows. Cortical: frontal 
(Brodmann 9), temporal (Brodmann 22), parietal (Brodmann 39), occipital and motor, or 
precentral, and insular cerebral cortices and gyrus cinguli and hippocampus, including the 
subiculum and entorhinal cortex. Subcortical: basal forebrain, including amygdala, basal 
ganglia and thalamus. Subtentorial: midbrain, including substantia nigra, pons, medulla, 
cerebellar cortex, vermis and dentatus. All specimens were embedded in paraffin.
For electron microscopy, autopsied tissue from the human brainstem was obtained from 
a neurologically unimpaired male subject, age at death 68 years. The tissue was cut into 
0.5cm thick slices and fixed in 4% formaldehyde (in 0.1M phosphate buffer, pH 7.4) 
overnight. The slices were then cut at 50μm with a vibratome (Leica VT 100S, Leica 
Instruments GmBH, Wetzlar, Germany). 
4.2.3 Motor neuron disease- related samples obtained at clinical autopsy (IV) 
Brain specimens were obtained from nine subjects (age 35-82 years at death) that had 
shown clinical symptoms of MND. In the neuropathological examination, most of the cases 
fulfilled the criteria for ALS, i.e. both lower and upper motor neuron involvement was 
noted. However, a case merited the histopathological diagnosis of progressive muscular 
atrophy when upper motor neurons were intact. The diagnosis of frontotemporal lobar 
degeneration with ubiquitinated inclusions and ALS (FTLD-u/ALS) was applied when, in 
addition to widespread ubiquitin immunoreactive lesions, clinical signs of dementia had 
been registered. Thus, 7 cases fulfilled the criteria for ALS, whereas one was diagnosed as 
progressive muscular artrophy and one as FTLD-U/ALS.  
All cases were negative for -synuclein in substantia nigra. All cases were Braak-staged 
and the clinical records were re-examined. The one case that had been diagnosed with 
frontotemporal dementia also had the diagnosis of paranoid schizophrenia. In addition, 
three other subjects had been diagnosed with a non-psychotic psychiatric disorder. None of 
the examined cases had any history of skin disorders.  
At autopsy, all the brains were fixed and dissected in the same way as the non-
neuropathological samples described above. Brain specimens were taken from cortical, 
subcortical and subtentorial gray matter structures as follows: frontal (Brodmann 9), 
temporal (Brodmann 22), parietal (Brodmann 39), occipital cortex including calcarine 
sulcus, up to five specimens from the motor cortex, hippocampus, midbrain including 
substantia nigra, medulla, cerebellar cortex and spinal cord.  
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7-μm-thick brain tissue sections from all blocks were cut for hematoxylin-eosin and IHC 
stains. For IHC, the sections were deparaffinized in xylene, rehydrated in graded alcohol 
series and subjected to epitope unmasking treatments.  
4.3 IN SITU HYBRIDISATION 
Radioactive in situ hybridisation was performed as previously described (Hurskainen et al. 
1996). In short, the paraffin sections were deparaffinized with xylene and dehydrated. For 
proteolysis the sections were incubated with proteinase K (100 g/ml). Acetylation was 
carried out in 0.25% to 0.5% acetic anhydride in 0.1M triethanolamine for 10min. 
Prehybridisation was carried out for 2 hrs at +50˚C. In order to produce the RNA probes, a 
cDNA fragment covering amino acids 1365-1497 of human collagen XVII ectodomain (Ecto-
4) was cloned into pGEM 4Z vector (Promega, Madison, WI, USA) and linearized with 
suitable restriction enzymes. RNA probes labelled with 35S-UTP (800Ci/mmol) were 
transcribed using a riboprobe transcription kit (Promega) (Parikka et al., 2003). The 35S-
UTP-labelled antisense or sense probe (3x 106 c.p.m) in 40-50 l hybridisation buffer was 
applied on each section and the hybridisation was carried out in a humid chamber at +50 C 
overnight. After posthybridisation washes, the sections were dehydrated in ethanol 
containing 0,3M ammonium acetate. For autoradiography the slides were dipped into NTB-
2 film emulsion (Kodak, New York, NY, USA) and placed in light-tight boxes for 12-14 
days. The slides were developed in D-19 (Kodak) developer, fixed in Agefix (Kodak) and 
counterstained with HE. Corresponding sense probes were always used as negative 
controls.   
4.4 RT-PCR 
RT-PCR followed by sequencing was performed in order to further confirm the presence of 
collagen XVII mRNA in the brain. After RNA isolation from the snap-frozen brain samples 
using TRIzol (Gibco, Invitrogen Co., Carlsbad, CA, USA) 1.5μg of total RNA was reverse 
transcribed to complementary DNA (cDNA) using M-MLV RT (Finnzymes, Helsinki, 
Finland) with random primers (Promega) and RNase inhibitor (Amersham Biosciences, 
Little Chalfont, UK). PCR assays were performed in 50μl volumes using 3μl of cDNA, 160 
μM of each nucleotide, 1 x reaction buffer, 1 U of Dynazyme polymerase (Finnzymes) and 
200nM of each specific primer. Collagen XVII and β-actin (control) reactions were done in 
separate tubes using the following primers: human collagen XVII (GenBank accession 
number M911669) 22-F (5’-GGAAGCCCTGGCCCTAAAGGTG AC-3’) and 22-R (5’-
AACCTCTCATGCCAGGCTCGCCTGT-3’), and human β-actin BA-F (5’-
TGCAGAAGGGAGTCACTGCC-3’) and BA-R (5’GTGAACTTTGGGGGATGCTC-3’). The 
PCR products were analyzed on 1% agarose gels, stained with ethidium bromide (EtBr), 
and visualized under ultraviolet light. As a control, human HaCaT keratinocyte total RNA 
was used. 
 After cloning to pCRII-TOPO vector (Invitrogen, Paisley, UK) the identity of the 
collagen XVII positive bands were confirmed by sequencing using the collagen XVII 
primers 22-F and 22-R. 
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4.5 IMMUNOHISTOCHEMISTRY 
4.5.1 Antibodies 
The antibodies used in this study are given in Table 4. All three collagen XVII antibodies 
used in this thesis were a gift from the Department of Dermatology, University of Freiburg, 
Germany, where they were developed and produced (Hofmann et al. 2009, Schönau 2009). 
The monoclonal NC16a-1 antibody specifically binds to the N-terminal part of the NC16a 
domain, whereas NC16a-3 recognizes a more C-terminal region. The NC16a- domain of 
collagen XVII is the part of the non-collagenous ectodomain that is situated adjacent to the 
cell membrane (Figure 1). The antibodies used are able to detect both the full-lengh and 
shed form of collagen XVII (Hofmann et al. 2009). The epitope of the polyclonal antibody 
used encompasses that of the monoclonal antibodies (Table 4) and is, as is typical for 
polyclonal antibodies, more sensitive but less specific than the monoclonal antibodies 
(Schönau 2009).    
Either the PowerVision+ Poly-HRP IHC Detection Kit (ImmunoVision Technologies, 
Brisbane, CA, USA) (II, IV) or  DAKO EnVision Detection Kit, Peroxidase/DAB, 
Rabbit/Mouse (DakoCytomation, Glostrup, Denmark) (I) was used for detection of coll 
XVII and for all other stainings, Histostain-Plus Bulk Kit (Zymed Laboratories, San 
Francisco, CA, USA) was employed. All stainings were visualized with Romulin AEC 
Chromogen (Biocare Medical, Concord, CA, USA). As a negative control, sections not 
incubated with the primary antibody were prepared. 
1
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4.6 WESTERN BLOT 
For Western blotting, samples of non-neuropathological human temporal cortex grey 
matter were used. Protein was extracted from the tissue using T-PERTM Tissue Protein 
Extraction Reagent (Thermo Fisher Scientific, Rockford, IL, USA). As a control, 100μg of 
protein extract was subjected to collagenase, as described previously (Claudepierre et al. 
2005), in order to verify the protein as a collagen. The samples were solubilized in Laemmli-
PAGE sample buffer, boiled for four minutes, resolved at 200V on 7.5% SDS-PAGE gel and 
electrophoretically transferred to ECL-nitrocellulose membrane (Amersham). Blots were 
blocked with 3% nonfat dry milk in Tris-buffered saline and 0.05% Tween-20. Membranes 
were probed for 3 hours at room temperature with the undiluted monoclonal collagen XVII 
antibody NC16a-3, washed and incubated for 2 hours with horse radish peroxidase-
conjugated sheep anti-mouse secondary antibody (1:4000, Amersham). Results were 
detected by Immobilon Western Chemiluminiscent HRP Substrate (Millipore, Billerica, MA, 
USA) and exposed against SuperRX-film (Fujifilm, Tokyo, Japan). 
4.7 ELECTRON MICROSCOPY 
4.7.1 Pre-embedding method 
Free-floating sections were washed in 0.1M phosphate buffer and then immersed in a 
solution containing 25% sucrose and 10% glycerol in 0.05M phosphate buffer. In order to 
increase the penetration of the antibodies, sections were freeze-thawed three times in liquid 
nitrogen. To block unspecific binding, sections were incubated in 10% normal goat serum in 
Tris-buffered saline for 40min. Sections were then incubated with the primary monoclonal 
antibody for collagen XVII (NC16a-1 undiluted and NC16a-3 1:100 solutions) for two days 
at 4°C. Negative control sections were incubated without the primary antibody. After 
extensive washings, sections were incubated with biotinylated horse anti-mouse (1:300, 
Vector #BA-2000) for 16h at 4°C and finally in avidin-biotinylated horseradish peroxidase 
complex (ABC, 1:500, Vector #PK-4000) for 3h at room temperature. The 
immunoperoxidase reaction was developed using 3,3-diaminobenzidine as a chromogen. 
During immunostaining, sections were washed with 1% normal goat serum in Tris-
buffered saline three times for 30min after each antibody solution.  After immunostaining, 
sections were processed for correlated light and electron microscopy. They were treated 
with 1% osmium tetroxide (OsO4) for 1 hour, dehydrated in graded ethanol and propylene 
oxide, and embedded in Durcupan (AMC) (Fluka, Sigma-Aldrich, St. Louis, MO, USA) 
between a glass microscope slide and coverslip. After polymerization at 60°C, sections were 
first studied and photographed under the light microscope. Then the coverslip was 
removed and the areas of interest were cut out from the section and re-embedded for 
further ultrathin sectioning. Ultrathin sections were mounted on copper grids.  
4.7.2 Post-embedding method 
Sections were first washed in 0.1M phosphate buffer and then dehydrated in graded 
ethanol and embedded in LR White (London Resin Company Ltd, London, UK) containing 
accelerator followed by mounting between a glass microscope slide and coverslip. After 
polymerization at 60°C, the coverslip was removed and the areas of interest were cut out 
from the section and re-embedded for ultrathin sectioning. A neighbouring section stained 
with thionin was used to provide landmarks for the suitable area. Ultrathin sections were 
cut on nickel grids and stained using the immunogold technique. The staining was carried 
out on droplets in a humid Petri dish. Sections were first treated with 0.05M glycine in 
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phosphate buffered saline for 15min and then for 15min in a solution containing 5% bovine 
serum albumin and 0.1% cold water fish skin gelatine in phosphate buffered saline. After 
washing in 0.1% BSA-c in phosphate buffered saline, sections were incubated in the 
primary antibody (monoclonal NC16a-3 1:100 or polyclonal NC16a 1:100 solutions) for 2h 
at room temperature. Then they were incubated in goat anti-mouse IgG (GAM) conjugated 
to 15nm gold particles (1:30) (Aurion, Wageningen, The Netherlands) or in protein A (1:30) 
conjugated to 14nm gold particles, respectively. Antibody dilutions were made in 0.1% 
BSA-c in phosphate buffered saline containing 0.5% Tween 20. Sections were washed with 
1% normal goat serum in Tris-buffered saline six times for 5min after each antibody 
solution. All ultrathin sections were treated for 30min in uranyl acetate and for two minutes 
in lead citrate in order to improve the contrast.  
4.7.3 Analysis 
The sections were examined in a Jeol (Tokyo, Japan) 1200 EX electron microscope at 80kV. 
The light microscopy digital micrographs were taken with an Olympus (Tokyo, Japan) 
DP50 digital camera mounted on an Olympus BX40 microscope. For verifications of 
autofluorescence, the samples were viewed under fluorescence light. For excitation, 
bandpass filter 460-490nm was used and emission was detected using BA520IF highpass 
filter.  
4.8 ETHICAL ASPECTS 
This study has been reviewed and approved by the ethics committees of The Northern 
Ostrobothnian Hospital District and Kuopio University Hospital. It adheres to the Finnish 
law concerning the use of human tissues for research purposes (Laki ihmisen elimien, 
kudoksien ja solujen lääketieteellisestä käytöstä 2.2.2001/101). This study in no way affected the 
standard diagnostic procedures for which the autopsies were performed.  
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5 Results 
5.1 COLLAGEN XVII RNA IS EXPRESSED IN NEURONS OF THE HUMAN 
BRAIN (I) 
Neuropathologically unimpaired human brain tissue was used for in situ hybrdisation, RT-
PCR and sequencing. In situ hybrdisation results demonstrated that collagen XVII mRNA 
was present in neurons, predominantly in the pyramidal cells, in all sections of all of the ten 
forensic cases. The localization was clearly concentrated to soma and proximal axon. The 
sense probe used as a control detected no signals in any of the brain samples (Figure 2). 
Using tissue from the hippocampus and amygdala, RT-PCR and sequencing further 
confirmed the presence of collagen XVII mRNA in the human brain.  
 
 
Figure 2. A) In situ hybridization 
with a collagen XVII RNA antisense 
probe in the human hippocampus. 
The probe has a strong affinity to 
neurons (some marked by arrows). 
B) The same sample using a sense 
probe as a control. Note the lack of 
binding in neurons (some marked 
with arrows) or elsewhere. 
Magnification x200. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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5.2 COLLAGEN XVII IS WIDELY EXPRESSED IN THE HUMAN BRAIN (I, 
II) 
Using IHC, collagen XVII was detected in nearly all of the studied brain regions, although 
the immunoreactivity (IR) did vary markedly from one area to another (see Table 5 for 
exact details). Areas of consistently prominent IR were the hypoglossal nucleus (nucleus 
XII), oculomotor nucleus (nucleus III), nucleus basalis of Meynert, supraoptic nucleus, 
subthalamic nuclei and pyramidal cells of the hippocampal regions of cornu ammonis (CA) 
4-2. In the cerebral cortex, staining was strongest in the deeper layers, i.e. layer V 
(ganglionic layer) but expression varied somewhat from one cortical area to another. IR was 
most prominent in the motor cortex, which is mainly accounted for by strong staining of 
Betz cells. In contrast, either none at all or only very faint IR was seen in the granular cells 
of the hippocampal CA and cerebellar cortex, and in the neurons of the mamillary body 
and caudatus.  
In some brain regions, particularly in the cerebral cortex, basal ganglia, and the 
cerebellum, collagen XVII-IR varied from one case to another. The differences in IR were 
not associated with age or gender, and only one clear association with pre-mortem events 
could be deduced: there was an almost total lack of collagen XVII-IR in the one case that 
suffered pre-mortem cerebral hypoxia and that displayed numerous ischemic neurons in 
the brain samples (Table 5, case 11).  
On a cellular level, the staining primarily localised to the cytoplasm of the cell body in 
either a diffuse or a slightly granular pattern (Figure 3), though there was also a light 
staining of the neuropil. No staining of white matter was seen and neither glial cells nor 
endothelial cells were labelled. In contrast, the ependymal lining was clearly stained. 
Western blotting using human brain tissue failed to recognize the expected 180kDa α-
chain band of collagen XVII. Instead, a single band of ca. 150kDa was detected (original 
publication II, figure 2). It was subjected to collagenase digestion, which obliterated the 
band, supporting the authenticity of the antigen as a collagen. Therefore, the detected 
150kDa size could be caused by partial degradation of collagen XVII by endogenous 
proteases during the post-mortem delay. 
 
 
Figure 3. A 
section of human 
hippocampus 
labeled using a 
polyclonal 
collagen XVII 
Nc16a antibody. 
Note the labeling 
of the pyramidal 
neurons (some 
marked by 
arrows) 
throughout the 
pictured area. 
Magnification 
x200. 
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5.3 THE INTRANEURONAL LOCALISATION OF COLLAGEN XVII IS TO 
LIPOFUSCIN GRANULES (III) 
In order to define the intraneuronal localisation of collagen XVII, electron microscopy on 
human brain samples was utilized. In line with the in situ hybridisation and IHC results, 
collagen XVII- IR was seen in the cell soma and proximal dendrites of large to medium-
sized neurons, although usually only in less than 10% of the neuronal population. The IR 
was concentrated in irregularly-shaped granules around the nucleus. (Figure 4A). 
Correlated light and electron microscopy revealed that these granules had the appearance 
of lipofuscin (Figure 4B and C) and they were confirmed to be lipofuscin due to their 
autofluorescence under fluorescent light.  
As is typical for lipofuscin, these granules were membrane-bound particles having two 
different compartments: one containing more electron-dense, dark substance and one 
containing more translucent material. However, in contrast with the usual appearance of 
lipofuscin granules, those cells that were immunopositive for collagen XVII had even 
darker granules within the darker lipofuscin compartment (Figure 4C). Furthermore, the 
lighter compartment had lost its translucency and was darker than what is usually seen in 
lipofuscin. 
In order to confirm the presence of collagen XVII within these lipofuscin granules, the 
immunogold technique was used (Figure 4D). Indeed, gold particles conjugated to the 
secondary antibody were found to locate to lipofuscin granules in the same way as 
described above, using both the monoclonal and polyclonal antibodies.  
Omission of the primary antibody was used as a control, and resulted in negligible 
staining and presence of gold particles. 
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Figure 4. A) With the light microscope, collagen XVII-IR is seen as cytoplasmic clusters in the 
neuron soma. Scale bar 10μm. B) Correlated electron microscopy of the neuron shown in A 
reveals that the immunoreactivity is located to granules having a lipofuscin-like appearance. 
Scale bar 5μm. C) High power electron microscopy shows that within the darker compartment 
of the lipofuscin particles, there are unusual electron-dense granules. Furthermore, the lighter 
compartment of lipofuscin is darker than in normal lipofuscin. Scale bar 2μm. D) In 
immunogold- stained sections, gold particles (small black particles) are found both in the dark 
and light lipofuscin compartments. Scale bar 0,5μm. 
A B 
C D 
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5.4 MOTOR NEURON DISEASE DOES NOT ALTER THE EXPRESSION OF 
NEURONAL COLLAGEN XVII (IV) 
Based on previous work pointing towards a possible role of CNS collagen in the 
pathogenesis of ALS (see for example (Chosidow et al. 2000, Ono et al. 1998), we decided to 
study collagen XVII- expression in brain samples affected with MND. However, we found 
the expression of collagen XVII in MND cases to be the same as in unaffected subjects. It 
should be mentioned, though, that collagen XVII- IR was seen also in frontal horn α-motor 
neurons in the MND- samples, but we have no data of collagen XVII expression in the 
spinal cord of neurologically unimpaired cases for comparison.  
The collagen XVII- IR was widely dispersed in the neuronal cytoplasm as usual, whereas 
the staining of p62, a robust marker of neuronal inclusion bodies (Kuusisto et al. 2008), was 
sharp and demarcated to the NCIs and neurites in all 9 subjects. There was no correlation 
between the intensity of the collagen XVII-IR and the quantity of p62-positive neurites or 
NCIs (nonparametric Spearman's correlation tests).  
Both TDP-43- and p62-IR was seen in the motor cortex, at the level of the medulla in the 
nucleus hypoglossus, and in the spinal cord in all cases, as expected in MND. However, in 
addition, p62-IHC visualized NCIs in the frontal cortex, in the hippocampus (both the 
granular cell layer of the dentate gyrus and CA4 region), and in the cerebellum in subjects 
with a clinical history of psychiatric morbidity. 
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6  Discussion 
6.1 THE STRENGTHS AND LIMITATIONS OF THE STUDY 
The present study has made use of current standard research methods and therefore relies 
heavily on their validity.  
All the tissue studied has been from humans and obtained at autopsy. In many ways, 
human brain samples are the most appropriate tissue for studies on brain disorders, but 
high-quality samples are also the most difficult to obtain. Samples are collected post-
mortem, and lack the kind of pre-mortem control that animal studies and cell lines derived 
from lymphocytes or fibroblasts can be subjected to. For instance, heterogeneity in cause of 
death, pre-mortem medical interventions, lifestyle habits, such as alcohol and drug 
consumption, smoking and dietary preferences, can cause difficulties in interpreting 
results.  Also, agonal and post-mortem events, such as rapidity of death and the interval 
between death and appropriate tissue storage, may influence the results obtained (Konradi 
et al. 2011).  
However, in this study care has been taken to define the quality of the tissues and to 
ensure that they fulfil the requirements for the methods used (Hynd et al. 2003). For 
instance, a long fixation time can compromise antigen retrieval and result in false negative 
findings, but in the clinical tissue samples, where the fixation time was exactly recorded, 
the maximum time was 65 days, which can be considered short- term fixation (Pikkarainen, 
Martikainen et al. 2010). In addition, the epitopes probed with the collagen XVII antibodies 
seemed to be relatively insensitive to agonal and post-mortem changes: no difference in 
collagen XVII-IR was seen in relation to post-mortem delay, which ranged from 48 to 124 h, 
or the fixation time. Likewise, no differences in collagen XVII-IR were noted between 
subjects dying instantaneously or within 24 h after the onset of symptoms but lacking signs 
of cerebral ischemia. The only noted influential variable was a prolonged mode of death, 
causing irreversible ischemic damage and depletion of collagen XVII-IR (study II). A 
notable exception is the Western blot. Here, although recognized by collagen XVII 
antibodies, the size of the detected protein differed from that expected in keratinocytes (c.a. 
150kDa vs. 180kDa). This could be due to post-mortem degradation and, indeed, earlier 
work has also reported a band differing from the expected size (less than 110kDa) due to 
apparent degradation (Claudepierre et al. 2005)  but no absolute answer can be given 
within the scope of this thesis. It is worth noting, though, that subsequent work (J. Chen, Li 
et al. 2011) has been able to demonstrate the full length 180kDa collagen XVII product in the 
human brain.   
In order to ensure specific antibody binding to collagen XVII, three antibodies, targeting 
different epitopes, have been used. The results were identical, as was the localisation of 
collagen XVII mRNA using in situ hybrdisation: all methods localized collagen XVII to the 
soma and proximal cell extensions.   
The autopsied brain material in study III consisted of a single 68-year old male. Because 
lipofuscin accumulates in the aging brain, and is largely originated from autophagocytosed 
mitochondria (Terman and Brunk 2006), one is tempted to speculate that in a younger brain 
the intracellular location could be elsewhere.   
Finally, it must be mentioned that the decision to study MND in relation to collagen 
XVII- expression (IV) was made based on research available at the time (2007-2008). 
However, subsequent work (Bastuji-Garin et al. 2011, Y. J. Chen, Wu et al. 2011, Jedlickova 
et al. 2010, Langan et al. 2011, Taghipour et al. 2010) points towards dementia, primarily 
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Alzheimer’s disease, and cerebral stroke having a more probable pathogenetic connection 
with collagen XVII. Therefore, the fact that these diseases were not studied within this 
thesis must be considered a limitation.    
6.2 THE POSSIBLE ROLE OF COLLAGEN XVII AS A COMMON ANTIGEN IN 
NEUROLOGICAL AND IMMUNOBULLOUS SKIN DISORDERS 
By demonstrating that collagen XVII is present in the human brain, our study raises the 
possibility of collagen XVII having a role in neurological disorders, particularly in 
association with subsequent BP. Some authors have discussed the possibility that BPAG1, 
or BP230, the other antigen targeted in BP, could be the common autoantigen in 
neurological and dermatological disorders, as variants of BPAG1 are expressed in the 
nervous system (Garcia-Estevez et al. 2008, Laffitte et al. 2005, Li et al. 2009). Indeed, 
antibodies in the serum of patients with both BP and neurological disease, primarily 
cerebrovascular disease, have been shown to recognize proteins corresponding to BPAG1 
in mouse brain extract (Li et al. 2009). It is interesting, however, that inspection of the 
immunoblots in Li and colleagues’ study reveals that in one case the serum reacts with a 
180 kDa protein, which is compatible with coll XVII, and subsequent work (J. Chen, Li et al. 
2011) found that sera of BP-patients with neurological disease reacted with both 230 and 
180 kDa antigens in human brain extract, corresponding to BPAG1 and collagen XVII, 
respectively. Also, immunoblotting of the cerebrospinal fluid of MS patients against BPAG1 
has revealed only a low frequency of reactivity (Laffitte et al. 2005). What is more, in reply 
to Foureur and colleagues (2010), Wieland et al. specify that in their study of collagen XVII 
and BPAG1 autoantibodies in the serum of 337 individuals with no signs of BP (Wieland et 
al. 2010), of the 25 found to be positive, 5 had neurologic diseases listed in their medical 
records. In all but one case, the amount of BP180, i.e. collagen XVII, antibodies, as measured 
with enzyme-linked immunosorbent assay (ELISA), is greater than that of BP230. These 
findings underline the possibility that collagen XVII, the primary autoantigen in BP 
(Thoma-Uszynski et al. 2004), could be the common etiopathogenetic denominator in 
dermatological and neurological disorders, perhaps in addition to BPAG1. On the other 
hand, Soni (2009) found evidence of neither collagen XVII nor BPAG1 antibodies in a case 
of autoimmune encephalopathy with BP, raising the possibility of an antigenic target 
common to both the skin and CNS which is neither of the above. 
In any case, when both BP and neurological disorder are present, neurological disease 
usually precedes BP (J. Chen, Li et al. 2011, Langan et al. 2011) by months to years (Cordel 
et al. 2007, Stinco et al. 2005). This supports the idea that neuronal antigen exposure, 
conceivably via a compromised blood-brain barrier, is causatively involved in subsequent 
development of BP.  In light of this, the hypothesis of immunoglobulin- mediated 
neurodegeneration in Alzheimer’s disease (Bouras et al. 2005)  is particularly intriguing, as 
dementia is the disorder most consistently associated with BP. This hypothesis involves an 
age-related compromise of the blood-brain barrier (Zeevi et al. 2010) and loss of the 
“immunological privilege” of the brain. In a murine model of senescence, vascular 
permeability to the brain has been shown to be particularly prevalent in the hippocampal 
region (Pelegri et al. 2007), where we have shown strong collagen XVII expression and 
which is a well-recognized predilection area for Alzheimer’s disease-related lesions (Barnes 
et al. 2009).  Notably, mRNA of ADAM 10, the metalloprotease responsible for the cleavage 
of the extracellular domain of collagen XVII and which is also implicated in processing the 
amyloid precursor protein (Jorissen et al. 2010), is also detectable  in the same anatomical 
areas as collagen XVII, including the hippocampus (Kärkkäinen et al. 2000).   
The other condition most frequently reported in association with BP is cerebrovascular 
disease, or stroke (Table 2). Of course, etiopathogenetically, this is not a neuronal disease, 
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but vascular in origin. Therefore, it is interesting that in contrast with neurological disease 
in general, stroke has been shown to often occur also after the onset of BP (Yang et al. 2011). 
This could be explained by the fact that the inflammatory state present in BP is not confined 
to the skin but also involves vascular endothelium (Ameglio et al. 1997), as does the 
pathogenesis of atherosclerosis, atheroma plaque rupture and thrombosis (Ross 1999). Also, 
there is some evidence that antiphospholipid antibodies are present in the serum of BP- 
patients (Echigo et al. 2007). Thus, the BP- associated inflammation, perhaps together with 
the hypercoagulable state associated with antiphospholipid antibodies, could exacerbate 
pre-existing atherosclerosis and promote thrombosis and stroke (Yang et al. 2011). 
In terms of inflammation, the recent findings linking affective disorder and 
schizophrenia with BP (Bastuji-Garin et al. 2011, Y. J. Chen, Wu et al. 2011) are interesting, 
as there is evidence of upregulation of immune response genes in these disorders (Konradi 
et al. 2011).  In fact for schizophrenia, a neuroimmune hypothesis has been debated for 
decades (Arion et al. 2007). Although the current consensus concerning the inflammatory 
etiology of schizophrenia involves the idea of a long-lasting consequence of an infective-
immune challenge during early brain-development, numerous other explanations have 
been offered, including autoimmunity towards brain structures (Pandey et al. 1981), 
particularly in the hippocampus (Ganguli et al. 1993). However, as inflammation is also 
closely linked with behavioral parameters such as exercise, alcohol abuse, and smoking, as 
well as with medical conditions including coronary artery disease, obesity and insulin 
resistance (Goldstein et al. 2009), interpreting the inflammatory findings in psychiatric 
disease is exceedingly complex (Sperner-Unterweger 2005).   
Although there is a case report in which mental retardation has been present with 
junctional epidermolysis bullosa (Nakar et al. 1992), it is not a common feature (Pfendner 
and Lucky 2008). Genetic studies concerning collagen XVII involvement in CNS- pathology 
are beyond the scope of this thesis. 
6.3 LIPOFUSCIN 
Lipofuscin is an undegradable autofluorescent pigment that accumulates in aging, 
postmitotic cells, including neurons, throughout the animal kingdom (Double et al. 2008, 
Sulzer et al. 2008). It is usually considered waste material, the accumulation of which has a 
detrimental effect on various cellular functions, particularly by interfering with lysosomal 
degradation (Brunk and Terman 2002). Although lipofuscin is produced by nearly all brain 
cells, it is, similarly to collagen XVII, most abundant in larger neurons and in brain areas 
involved in movement (Double et al. 2008).  
Physiologically, lipofuscin can be thought of as the end-product of incomplete 
degradation of various cytoplasmic substances through autophagy. Autophagy is an 
evolutionarily conserved catabolic process, the function of which is to maintain cellular 
homeostasis by, for instance, clearing out damaged intracellular organelles and 
macromolecules, eliminating pathogens and suppressing tumour growth (Kang et al. 2011). 
The final breakdown of these intracellular substances to simple, recyclable molecules takes 
place within lysosomes by various degrading enzymes, such as hydrolases and proteases. 
However, due to intra- and intermolecular cross-links being formed by oxidation products 
of various cellular components, insoluble and non-degradable material accumulates and 
aggregates over time: this material is referred to as lipofuscin (Jung et al. 2007). The 
primary constituents of neuronal lipofuscin are oxidatively modified protein (30-58%) and 
lipid clusters (19-51%) (Sulzer et al. 2008, Terman and Brunk 2004), which largely originate 
from oxidatively damaged mitochondria (Terman and Brunk 2006).  
That having been said, it has been argued that there is not just one type of lipofuscin, but 
that this term encompasses a variety of differing lipopigments (Seehafer and Pearce 2006). 
30 
 
 
Indeed, the presence of collagen XVII in a specific, ultrastructurally definable type of 
lipofuscin granule supports this idea and may be helpful in the process of further exploring 
and defining the variety of neuronal lipopigments.  
Although our results show that collagen XVII expression was confined to lipofuscin, it is 
tempting to speculate that in a younger brain the intracellular location of collagen XVII 
could be different. It is worth noting, though, that both BP and the neurological morbidity 
most strongly associated with BP, particularly dementia, are associated with aging, as is the 
accumulation of neuronal lipofuscin. However, what the function of neuronal collagen XVII 
is and whether or not it has a role in any neuropathological or –physiological processes, we 
have not been able to discover within the scope of this thesis. That notwithstanding, the 
suggestion that lipofuscin actually benefits the neuron by incorporating potentially 
damaging metabolites (Stojanovic et al. 1994) is of great interest. Indeed, neuronal 
populations that regularly contain abundant lipofuscin are among the most resistant to age-
related degenerative changes (Gray and Woulfe 2005) and, more specifically,  there is 
evidence that lipofuscin plays a neuroprotective role in Parkinson’s disease (Kanaan et al. 
2007). 
6.4 P62 AND CLINICAL PRESENTATION IN MND 
During the last decade, there has been increasing awareness of the overlap between 
frontotemporal dementia and ALS (Lillo et al. 2010). Previous research has suggested that 
an alteration in collagen metabolism may take place in ALS (Ono et al. 1998, Ono et al. 1999, 
Ono et al. 2001), that BP may be associated with ALS (Chosidow et al. 2000) and several 
studies have associated dementia with BP (Table 2). However, we found no evidence of a 
change in collagen XVII- expression in either brains from ALS- or ALS with frontotemporal 
dementia- patients.     
On the other hand, we found that in MND p62-IR inclusions were present not only in the 
pyramidal motor system but more widely in the CNS. Interestingly, the distribution of p62-
IR varied according to clinical presentation: psychiatric disorders had been diagnosed only 
in the four subjects with p62-IR NCIs in the frontal cortex, hippocampus and cerebellum. 
Also, the only case in study IV with the diagnosis of frontotemporal dementia and ALS also 
had a diagnosis of paranoid schizophrenia, which supports the findings by Lillo et al. 
(2010) that psychotic symptoms are relatively common in frontotemporal dementia- 
patients who go on to develop ALS.  However, the other psychiatric diagnoses in our cases 
were non-psychotic and all differed from each other (please see article IV, Table 3 for 
details), so no absolute conclusions should be made based on these findings. It can merely 
be speculated whether some of the diagnosed psychiatric disorders, such as personality 
disorder, in fact represent the prodromal phase of a psychotic or dementing disease. In any 
case, our findings support the idea to think of ALS not only as a disease affecting the 
pyramidal motor system, but as a multisystem proteinopathy with a wide 
clinicopathological spectrum (Geser et al. 2008), including psychiatric morbidity.  
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7 Conclusions 
A number of earlier animal, case, and epidemiological studies have pointed towards the 
possibility of collagen XVII having a physiological and pathological role in the human 
central nervous system. In this thesis our knowledge of collagen XVII in humans was 
expanded by the following conclusions: 
 
1. Collagen XVII is expressed in human CNS neurons and is widely distributed in the  
human brain. 
 
2. Neuronal collagen XVII is localised to lipofuscin granules.   
 
3. A change in the expression of collagen XVII in the human brain is not an  
immunohistochemically detectable feature of motor neuron disease. 
 
4. The presence of p62- positive inclusions outside the motor system in motor neuron  
disease could be a marker for psychiatric morbidity.  
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Collagens have previously been over-
looked for roles in the brain since fibril-
lar collagens, the best known and most 
widely studied example of collagens, 
are not present in the mature central 
nervous system. However, over the 
last decade it has become increasingly 
apparent that collagens are not merely 
structural proteins giving strength to 
tissue, but bio-active molecules with a 
dynamic role within the nervous sys-
tem. Collagen XVII particularly has 
been emerging as a putative antigen 
common to both dermatological and 
neurological disease. In this thesis 
these lines of thought found support as 
collagen XVII was found to be widely 
expressed in neurons of the human 
brain. Its exact function in the brain, 
however, remains unknown. 
 
